Head-To-Head Survey: Adherex Technologies (NASDAQ:FENC) & Immix Biopharma (NASDAQ:IMMX)

Immix Biopharma (NASDAQ:IMMX) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Immix Biopharma and Adherex Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1	1	7	0	2.67
Adherex Technologies	1	1	4	1	2.71

Immix Biopharma currently has a consensus price target of $20.67, indicating a potential upside of 86.02%. Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 46.81%. Given Immix Biopharma’s higher probable upside, equities analysts clearly believe Immix Biopharma is more favorable than Adherex Technologies.

Risk and Volatility

Immix Biopharma has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Profitability

This table compares Immix Biopharma and Adherex Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Institutional & Insider Ownership

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Immix Biopharma and Adherex Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44 million	($0.92)	-12.08
Adherex Technologies	$51.00 million	7.18	-$9.74 million	($0.29)	-36.17

Adherex Technologies has higher revenue and earnings than Immix Biopharma. Adherex Technologies is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Adherex Technologies beats Immix Biopharma on 9 of the 14 factors compared between the two stocks.

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.